CoChat

Combining chemotherapy with PD-1 blockade in NSCLC

Mathew, Matthen, Enzler, Thomas, Shu, Catherine A., Rizvi, Naiyer A. · 2018 · Pharmacology & Therapeutics
Cited by 145

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Antitumor immunity relies on the ability of the immune system to recognize tumor cells as foreign and eliminate them. An effective immune response in this setting is due to surveillance of tumor‐specific antigens that induce an adaptive immune response resulting in T‐cell mediated cytotoxicity. Immune checkpoint inhibitors, specifically those targeting the programmed cell death‐1 (PD‐1)/programmed cell death ligand‐1 (PD‐L1) axis, have demonstrated promising activity in non‐small cell lung cancer (NSCLC). However, there remains a crucial need for better treatment strategies for the majority of patients with advanced NSCLC, particularly in the frontline setting. Chemotherapy can increase antigenicity via immunogenic cell death (ICD) of tumor cells as well as also reduce “off target” immunosuppression in the tumor microenvironment (TME). Combining chemotherapy with PD‐1 blockade harnesses the potential synergy between these agents and has led to encouraging results in the up‐front treatment of NSCLC. In this review, we summarize the preclinical rationale behind these combinations and review recent trial data demonstrating their efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2018.01.003

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 145

Metadata

Authors
Mathew, M., Enzler, T., Shu, C. A., & Rizvi, N. A.
Venue
Pharmacology & Therapeutics
Publisher
Elsevier BV
Published
2018-06
Volume
186
Pages
130-137
ISSN
0163-7258 (ISSN-L)
OpenAlex
W2792286951
Cited by
145
References
20
FWCI
4.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combining chemotherapy with PD-1 blockade in NSCLC. https://app.cochat.ai/papers/10.1016/j.pharmthera.2018.01.003
The paper
Mathew, M., Enzler, T., Shu, C. A., & Rizvi, N. A. (2018). Combining chemotherapy with PD-1 blockade in NSCLC. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2018.01.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.